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Abstract
Background: Unintended exposure to antitumor agents from an oral medicine may place healthcare workers and
patients taking medicine at risk. In this study, the exposure to blister pack by CP (cyclophosphamide) and
appropriate preventive procedures were examined.
Findings: CP detected inside the blister pack of the tested seven lots by LC-MS/MS ranged from 8.2 to 199.6 ng. Raman
imaging clearly showed that CP ingredient was completely covered by the tablet coating layer and had not leached out
of the tablet. In addition, the amount of CP detected inside the vials was suppressed under the lower detection limit until
day 28, and only 6.0 ng was detected only at day 56.
Conclusions: Various amounts of CP were contaminated to not only the inside of the blister pack but also the outside.
This contamination may be caused not only by the manufacturing environment but also by the CP oral tablets
themselves through volatilization of CP. Refrigerated storage of CP oral tablets may protect healthcare workers and
patients from contact with CP.
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Background
Although antitumor agents are very widely used for the
treatment of cancer, they pose a risk to healthcare
workers who handle the drugs or work in their vicinity
and in patients, even at very low concentration. Expos-
ure by antitumor agents to healthcare workers has been
extensively studied over the last two decades. Antitumor
agents have been detected in urine, blood and skin from
healthcare workers and also in their work environment
[1–3]. To prevent the exposure by antitumor agents,
country-specific guidelines have been established and
closed system devices have been used [4]. However, ex-
posure of healthcare workers to antitumor agents is still
observed.
Cyclophosphamide (CP), one of volatile antitumor
agents, is also one of the most frequently used drugs. Ex-
posure to CP in various healthcare working environments
has been found with contamination of working trays,
floors, surfaces inside biological safety cabinets, door han-
dles, and injection vials [5, 6]. CP contamination on the
surface of injection vials has been well examined; however,
possible contamination on blister packs has been only
rarely investigated [7]. The exposure by antitumor agents
from oral medicine may place the healthcare workers and
patients taking the medicine at risk. Here we evaluated
possible exposure to CP on blister packs and determined
ways to prevent CP exposure.
Materials and methods
Chemicals and materials
CP oral tablets (Endoxan® tablets) were obtained from
Shionogi Co. Ltd. Cyclophosphamide monohydrate as a
standard CP was obtained from Wako (Osaka, Japan).
Hexamethylphosphoramide (HMPA) as an internal stand-
ard was obtained from ALDRICH (St Louis, USA). All
other chemicals and solvents were of the highest analytical
grades available.
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Analytical procedure
Chromatographic separation was performed using High-
performance liquid chromatography system (Agilent 1100
series; Agilent, USA) and a CAPCELL PAK C18 MGII S-5
(100 mm× 2.0 mm; i.d., 3 μm; SHISEIDO, Japan) analyt-
ical column at 40 °C. The isocratic mobile phase consisted
of mobile phase-A (0.1 % formic acid) and mobile phase-B
(acetonitrile) (50:50, v/v) at a flow rate of 0.2 mL/min. The
solution was filtered using a 0.22 μm membrane.
Mass spectrometric detection was performed on an
ABSciex API 2000 triple quadrupole mass spectrometer
(ABSciex, Toronto, Canada). Data acquisition was per-
formed using the Analyst™ 1.6.1 software (AB Sciex, To-
ronto, Canada). The mass spectrometer was operated in
the positive ion mode. Optimized instrument settings spe-
cific atropine and IS were as follows: curtain gas was
30 psi, ion source gas 1 was 70 psi, ion source gas 2 was
80 psi, ionspray voltage was 4000 V, and turbo heater
temperature was 300 °C. Quantification was performed in
the multiple reaction monitoring (MRM) mode with
mass-to-charge (m/z) transitions at 261.2 > 140.1 for CP
and 180.2 > 135.1 for IS.
Preparation of the standard solution and quality control
samples
Stock solutions of both CP monohydrate and HMPA were
prepared at 1 mg/mL in methanol. The stock solutions of
CP were diluted to 5, 10, 20, 50, 100 and 200 ng/mL in
water containing 0.05 % formic acid and 50 % acetonitrile
in water. HMPA stock solutions were diluted and added
to both standard and sample solutions at the final concen-
tration of 30 ng/mL.
Sample preparation
To measure the amounts of CP attached inside and out-
side the blister pack separately, the blister pack was
washed twice. First, the blister pack containing the tab-
lets was washed by methanol with 10 min of sonication.
Next, the CP oral tablets were taken off from the blister
pack and residual empty blister pack was washed by
methanol with 10 min sonication. These sample solu-
tions were extracted and measured by LC-MS/MS
(Fig. 1).
Raman imaging
Detailed procedures for Raman imaging are described in
Additional file 1.
Results
The amounts of CP attached to both the inside and out-
side of each blister pack were separately measured using
LC-MS/MS. The CP extraction procedure is described in
Fig. 1. As a result, CP ranged from 8.2 to 199.6 ng was de-
tected inside the blister pack for all seven lots (Fig. 2a). In
addition, a broad range of CP (~302.7 ng) was also de-
tected outside the blister pack by some lots (Fig. 2a).
To clarify whether CP had leached out to the outside
the tablet, CP localization at a whole tablet or tablet cross
section was analyzed using a Raman imaging system.
Interestingly, Raman imaging clearly demonstrated that
the CP ingredient was completely covered by the coating
layer containing titanium oxide, with no evidence of leach-
ing (Fig. 2b and 2c).
Further, to examine whether the CP ingredient packed
in tablet could volatilize to outside of the tablet and, if
present, whether such CP volatilization could be sup-
pressed by low temperature storage, 5 CP oral tablets
were removed from a blister pack and the tablets were
stored in a vial at either room temperature (RT) or 4 °C
for 7, 14, 28 and 56 days. The average RT was 21.0 ± 1.7
(°C) during this experiment (see Additional file 2). Fol-
lowing storage, the CP attached to the inside of the vials
was quantified using LC-MS/MS, respectively. From
these analyses, CP was detected to be 8.0 ng inside a vial
stored at RT for 7 days, with the amount of CP detected
increasing significantly through day 56 (Table. 1). In
addition, the amount of CP detected inside the vials was
suppressed under the lower detection limit until day 28
and only 6.0 ng was detected at day 56.
Fig. 1 Schematic representation of sample preparation procedure prior to measurement of cyclophosphamide (CP) attached to the inside or
outside of a blister pack separately
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Discussion
In this study, we demonstrated that various amounts of
CP had contaminated both the inside and outside of the
blister pack. There are many reports of CP contamination
on the surface of CP injection vials and on their cap
covers [7–9]. However, there is currently only one report
of CP contamination on both the outside and inside of
blister packs. Hedmer et al. reported that 0.5 ng median
(range 0.2 − 3.5 ng) amounts of CP was detected on the
outside of CP oral tablet blister packs (Sendoxan 50 mg
tablets, Sweden) [7]. The authors have pointed out the
need for a proper cleaning of manufacturing facilities and
equipment to avoid such contamination. As presented in
Fig. 2a, the amount of CP detected outside of the blister
Fig. 2 The amount of CP on the inside and outside of the blister packs, and localization of CP within the Endoxan® tablet. a. The amount of CP
attached to the inside or outside of the blister pack was measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS). #1, #2,
#3 and #4 are replicate numbers assigned among the same lot. CP, cyclophosphamide; ND, not detected; < 3, below the detection limit (3 ng/
sheet). b and c. Raman chemical imaging of (b) CP oral tablet whole and (c) a CP oral tablet cross-section. Red area, CP; Yellow area, titanium
oxide; Green area, lactose hydrate
Table 1 Sequential change of CP amounts attached to inside of stocked vials
Stored periods
Day 7 Day 14 Day 28 Day 56
Amount of CPa(ng/vial) Vehicle RTb ND ND ND ND
4 °C ND ND ND ND
Endoxan® tablets RT 8.0 ± 1.2 10.3 ± 2.7 17.2 ± 2.0* 49.0 ± 6.7**
4 °C ND <3 <3 6.0 ± 1.0##
a) cyclophosphamide
b) room temperature
Data are represented by mean ± SD. *p < 0.05; **p < 0.01, Dunnet’s multiple comparison test; ##p < 0.01, unpaired t-test; ND; not detected, < 3; under the detection
limit (3 ng/vial)
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pack in Lot. D were unaccountably higher than those in-
side of the blister pack. In this experiment, all lots of blis-
ter packs were newly purchased. We ascertained all blister
packs uncorrupted. In addition, samples for measurement
and CP standard solutions were prepared on separate
table by separate experimenters to avoid artificial contam-
ination of CP. Thus, we think that outside of the blister
packs may be randomely contaminated with volatiled CP
from both the manufacturing environment and from the
CP oral tablets themselves. We evaluated the localization
of CP in whole tablet and tablet cross sections using a Ra-
man imaging system to clarify whether CP had leached
out of the tablet. However, tablet’s CP ingredient was
completely covered by the coating layer and had not lea-
ched outside the tablet (Fig. 2b and 2c). Thus, CP was
thought to have been volatilized from the tablet.
Furthermore, we showed that such CP contamination
through volatilization could be prevented by refrigerated
storage (Table. 1). Endoxan® tablets are generally recom-
mended for storage at room temperature. Our results
showed that CP contamination inside the blister pack
could be suppressed below the detection limit for at least
28 days by refrigeration (Table. 1). CP oral tablets are
often prepared as a one-dose package in Japan and are not
prescribed for more than one month because of efficacy
monitoring and the occurrence of adverse effects in
treated patients. In fact, the most frequently prescribed
period was 28 days from Jan 2015 to Mar 2015 at Muscat
Pharmacy (see Additional file 3). Thus, the refrigerated
storage of CP oral tablets may protect healthcare workers
and patients from unintended contact with the hazardous
agents, CP.
Findings
We demonstrated that various amounts of CP had con-
taminated both the inside and the outside of the blister
pack. This contamination could be because of both the
manufacturing environment and the CP oral tablets them-
selves through volatilization. We suggest refrigerated stor-
age of CP oral tablets to protect healthcare workers and
patients from unintended contact CP exposure.
Additional files
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Additional file 2: Supplementary Table.
Additional file 3: Supplementary Table.
Abbreviations
CP: Cyclophosphamide; HMPA: Hexamethylphosphoramide; LC-MS/
MS: Liquid Chromatography-tandem mass spectrometry; HPLC:
High-performance liquid chromatography.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
TH and YT: designed all experiments, performed the experiments, analyzed
data, and edited the manuscript; KM: analyzed localization of CP by Raman
imaging; MO, TO, HM and MT: provide Endoxan® tablet and meaningful
discussion; YI, AK, EK, AN, AH and AY: performed the experiments and
analyzed data; KS, MT and TE: coordinate this project. All authors read and
approved the final manuscript.
Authors’ information
Takae Hanada and Yoichiro Takami are co-first author.
Author details
1School of Pharmacy, Shujitsu University, 1-6-1 Nishigawara, Naka-ku,
Okayama 703-8516, Japan. 2Department of Pediatrics, Okayama University
Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan. 3Muscat
Pharmacy, 1290-1 Tamasu, Kita-ku, Okayama 701-1154, Japan.
Received: 25 April 2015 Accepted: 8 June 2015
References
1. Ensslin AS, Stoll Y, Pethran A, Pfaller A, Rommelt H, Fruhmann G. Biological
monitoring of cyclophosphamide and ifosfamide in urine of hospital
personnel occupationally exposed to cytostatic drugs. Occup Environ Med.
1994;51:229–33.
2. Nygren O, Lundgren C. Determination of platinum in workroom air and in
blood and urine from nursing staff attending patients receiving cisplatin
chemotherapy. Int Arch Occup Environ Health. 1997;70:209–14.
3. Fransman W, Kager H, Meijster T, Heederik D, Kromhout H, Portengen L,
et al. Leukemia from dermal exposure to cyclophosphamide among nurses
in The Netherlands: quantitative assessment of the risk. Ann Occup Hyg.
2014;58:271–82.
4. Sessink PJ, Trahan J, Coyne JW. Reduction in Surface Contamination With
Cyclophosphamide in 30 US Hospital Pharmacies Following Implementation
of a Closed-System Drug Transfer Device. Hosp Pharm. 2013;48:204–12.
5. Miyake T, Iwamoto T, Tanimura M, Okuda M. Impact of closed-system drug
transfer device on exposure of environment and healthcare provider to
cyclophosphamide in Japanese hospital. Springerplus. 2013;2:273.
6. Hedmer M, Tinnerberg H, Axmon A, Jönsson BA. Environmental and
biological monitoring of antineoplastic drugs in four workplaces in a
Swedish hospital. Int Arch Occup Environ Health. 2008;81:899–911.
7. Hedmer M, Georgiadi A, Bremberg ER, Jonsson BA, Eksborg S. Surface
contamination of cyclophosphamide packaging and surface contamination
with antineoplastic drugs in a hospital pharmacy in Sweden. Ann Occup
Hyg. 2005;49:629–37.
8. Mason HJ, Morton J, Garfitt SJ, Iqbal S, Jones K. Cytotoxic drug
contamination on the outside of vials delivered to a hospital pharmacy.
Ann Occup Hyg. 2003;47:681–5.
9. Connor TH, Sessink PJ, Harrison BR, Pretty JR, Peters BG, Alfaro RM, et al.
Surface contamination of chemotherapy drug vials and evaluation of new
vial-cleaning techniques: results of three studies. Am J Health Syst Pharm.
2005;62:475–84.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hanada et al. Journal of Pharmaceutical Health Care and Sciences  (2015) 1:20 Page 4 of 4
